Posters & Publications

Third Quarter 2026 Earnings Conference Call  Click Here

To view our PMN310 Scientific and Clinical Update (November 2026)   Click Here

Years of Research at Your Fingertips

ProMIS Neurosciences’ publications and posters provide ample background on our research surrounding neurodegenerative diseases.

Filter By:

PMN311 | AD Vaccine

Narration of Alzheimer's Disease Vaccine Presentation

View
PMN440 | A-Syn Vaccine

Alpha-synuclein Vaccine Presentation

View
PMN440 | A-Syn Vaccine

Narration of Alpha-synuclein Vaccine Presentation

View
PMN310 | Amyloid-Beta

Phase 1a Single Ascending Dose Study of PMN310, a monoclonal antibody directed against toxic Aβ oligomers

View
PMN310 | Amyloid-Beta

Distinguishing between Ab-directed antibodies: Ability of PMN310 to target toxic oligomers despite competing species

View
PMN311 | AD Vaccine

Novel approach to optimization of Alzheimer’s vaccine configuration for maximal targeting of toxic amyloid-beta oligomers

View
PMN310 | Amyloid-Beta

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

View
Discovery

Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration

View
PMN310 | Amyloid-Beta

Selective targeting and protection against toxic amyloid-beta oligomers by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease

View
PMN311 | AD Vaccine

Rational design of a vaccine for Alzheimer’s disease using a computationallyderived conformational epitope to selectively target toxic amyloid-beta oligomers

View
PMN311 | AD Vaccine

AAN 2023 Presentation – Rational design of a vaccine for Alzheimer’s disease using computationally-derived conformational B cell epitopes to selectively target toxic amyloid-beta oligomers

View
Discovery

AAN 2023 Poster – RACK1 Knockdown is a Potential Therapeutic Target in ALS and FTLD-TDP

View